The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists
Autor: | Zhe Bao Wu, Hao Tang, Wanqun Xie, Qun Li, Bohan Ren, Yongzhi Zheng, Zerui Wu, Zhipeng Su, Lin Cai, Yong Zhang, Yijun Cheng |
---|---|
Rok vydání: | 2020 |
Předmět: |
Adenoma
0301 basic medicine Mice Nude 030209 endocrinology & metabolism Biology Autophagy-Related Protein 7 Biochemistry Dopamine agonist Mice 03 medical and health sciences 0302 clinical medicine Endocrinology Cell Line Tumor Cabergoline microRNA medicine Animals Humans Pituitary Neoplasms Prolactinoma Molecular Biology Mice Inbred BALB C Messenger RNA Pituitary tumors medicine.disease Somatotrophs female genital diseases and pregnancy complications Bromocriptine Rats Gene Expression Regulation Neoplastic MicroRNAs 030104 developmental biology Drug Resistance Neoplasm Tumor progression Dopamine Agonists embryonic structures Cancer research Female RNA Long Noncoding Signal Transduction medicine.drug |
Zdroj: | Molecular and Cellular Endocrinology. 518:111033 |
ISSN: | 0303-7207 |
Popis: | Dopamine agonists (DAs), such as cabergoline and bromocriptine, are the first-line clinical treatment for prolactinomas. Our previous study demonstrated that long noncoding RNA H19 expression is frequently downregulated in human primary pituitary adenomas and is negatively correlated with tumor progression. However, the significance and mechanism of H19 in the DA treatment of prolactinomas are still unknown. In this study, we reported that H19 had a synergistic effect with DA treatment on prolactinomas in vitro and in vivo. Mechanistically, H19 promoted ATG7 expression in pituitary tumor cells by inhibiting miR-93a expression. In addition, a potential binding site between miR-93 and H19 was confirmed, and low expression of miR-93 was previously found in DA-resistant prolactinomas. Furthermore, we showed that miR-93a regulates ATG7 expression by targeting ATG7 mRNA. In conclusion, our study has identified the role of the H19-miR-93-ATG7 axis in DA treatment of prolactinomas, which may be a potential therapeutic target for human prolactinomas. |
Databáze: | OpenAIRE |
Externí odkaz: |